Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.33 |
| ▸ | PDE4A | P27815 | 7/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
| ▸ | PTGIR | P43119 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1809033 | 1.00 | ATF4 (0.42) | ATF4PRMT5WDR77CTSLPDE4D | |
| SCHEMBL2002142 | 0.89 | PRMT5 (0.39) | ATF4PRMT5WDR77ITGB3ITGA2B | |
| SCHEMBL360662 | 0.88 | ITGB3 (0.41) | ATF4PRMT5WDR77ITGB3ITGA2B | |
| SCHEMBL23216655 | 0.83 | — | — | |
| SCHEMBL28529903 | 0.78 | ATF4 (0.47) | ATF4PRMT5WDR77CTSLPDE4D | |
| SCHEMBL20345730 | 0.78 | ATF4 (0.47) | ATF4PRMT5WDR77CTSLPDE4D | |
| SCHEMBL1813151 | 0.77 | KMT2A (0.39) | ATF4PRMT5WDR77PDE4DPDE4A | |
| SCHEMBL29214555 | 0.77 | KMT2A (0.39) | ATF4PRMT5WDR77PDE4DPDE4A | |
| SCHEMBL1813150 | 0.77 | KMT2A (0.39) | ATF4PRMT5WDR77PDE4DPDE4A | |
| SCHEMBL24671886 | 0.75 | ATF4 (0.38) | ATF4PRMT5WDR77PDE4DPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114671864-B | Heteroaryl substituted pyridines and methods of use | 艾伯维公司 | 2025-04-08 | — | — | CN | disclosed |
| EP-3541802-B1 | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2025-01-01 | — | — | EP | disclosed |
| CN-116669738-A | Pyrimidopyridone derivative as SOS1 inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-116568689-A | Polycyclic pyrimidine derivative as SOS1 inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-115605479-A | Pyridoneopyrimidine derivative, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-114671864-A | Heteroaryl substituted pyridines and methods of use | 艾伯维公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-109311864-B | Heteroaryl substituted pyridines and methods of use | 艾伯维公司 | 2022-05-10 | — | — | CN | disclosed |
| US-11191762-B2 | Alkyl substituted triazole compounds as agonists of the APJ Receptor | AMGEN INC. (US) | 2021-12-07 | — | — | US | disclosed |
| EP-3560928-B1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD (CN) | 2021-10-20 | — | — | EP | disclosed |
| EP-3464282-A1 | HETEROARYL SUBSTITUTED PYRIDINES AND METHODS OF USE | AbbVie S.À.R.L. (LU) | 2019-04-10 | — | — | EP | disclosed |
| US-20190055229-A1 | Heteroaryl Substituted Pyridines and Methods of Use | ABBVIE S.Á.R.L. (LU) | 2019-02-21 | — | — | US | disclosed |
| US-10138227-B2 | Heteroaryl substituted pyridines and methods of use | ABBVIE S.Á.R.L. (LU) | 2018-11-27 | — | — | US | disclosed |
| EP-2593425-B1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | AGIOS PHARMACEUTICALS INC (US) | 2018-10-17 | — | — | EP | disclosed |
| WO-2018113624-A1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | 深圳微芯生物科技有限责任公司 | 2018-06-28 | — | — | WO | disclosed |
| US-20170349576-A1 | HETEROARYL SUBSTITUTED PYRIDINES AND METHODS OF USE | ABBVIE S.Á.R.L. (LU) | 2017-12-07 | — | — | US | disclosed |
| WO-2017208115-A1 | HETEROARYL SUBSTITUTED PYRIDINES AND METHODS OF USE | AbbVie S.à.r.l. (LU) | 2017-12-07 | — | — | WO | disclosed |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2011061590-A1 | NOVEL CARBOXAMIDE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11191762-B2 | Alkyl substituted triazole compounds as agonists of the APJ Receptor | AGTR1, AGTR2, APLNR | ATF4 316/4885PRMT5 2297/4885WDR77 1373/4885 |
| US-20170349576-A1 | HETEROARYL SUBSTITUTED PYRIDINES AND METHODS OF USE | CFTR, P2RX2, P2RX1 | ATF4 4474/4885PRMT5 901/4885WDR77 937/4885 |
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | ATF4 1343/4885PRMT5 317/4885WDR77 431/4885 |
| US-20190055229-A1 | Heteroaryl Substituted Pyridines and Methods of Use | CFTR, P2RX2, P2RX1 | ATF4 4474/4885PRMT5 901/4885WDR77 937/4885 |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | ATF4 1343/4885PRMT5 317/4885WDR77 431/4885 |
| US-10138227-B2 | Heteroaryl substituted pyridines and methods of use | CFTR, P2RX2, P2RX1 | ATF4 4474/4885PRMT5 901/4885WDR77 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.